77
Participants
Start Date
November 8, 2020
Primary Completion Date
June 30, 2023
Study Completion Date
June 30, 2023
trofinetide
Study drug is administered twice a day for up to approximately 32 months. Doses may be taken orally or administered by gastrostomy (G) tube. The subject's assigned dose for this study will be the final dose from the antecedent study (ACP-2566-004).
Montefiore Medical Center, The Bronx
Children's Hospital of Philadelphia, Philadelphia
Kennedy Krieger Institute, John Hopkins School of Medicine, Baltimore
The University of North Carolina at Chapel Hill, Chapel Hill
Greenwood Genetic Center, Greenwood
Emory Genetics Clinical Trial Center, Atlanta
University of South Florida, Tampa
University of Alabama at Birmingham, Birmingham
Vanderbilt University Medical Center, Nashville
Cleveland Clinic, Cleveland
Cincinnati Children's Hospital Medical Center, Cincinnati
Gillette Children's Specialty Healthcare, Saint Paul
Rush University Medical Center, Chicago
Washington University School of Medicine, St Louis
Texas Children's Hospital, Houston
Children's Hospital Colorado Aurora, Aurora
Translational Genomics Research Institute (TGen), Phoenix
University of California, San Diego, La Jolla
UC Davis MIND Institute, Sacramento
Seattle Children's Hospital, Seattle
Boston Children's Hospital Harvard Medical School, Boston
Lead Sponsor
ACADIA Pharmaceuticals Inc.
INDUSTRY